Oral dispersible vaccine comprising virosomes
US11224571B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 23, 2021 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Aug 23, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16123
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.